- Previous Close
1.6900 - Open
1.6900 - Bid 1.5700 x --
- Ask 1.7200 x --
- Day's Range
1.6900 - 1.6900 - 52 Week Range
1.5400 - 9.3500 - Volume
144 - Avg. Volume
4,625 - Market Cap (intraday)
5.448M - Beta (5Y Monthly) -0.21
- PE Ratio (TTM)
9.94 - EPS (TTM)
0.1700 - Earnings Date Mar 31, 2025 - Apr 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
www.xortx.comRecent News: XRTX.V
View MorePerformance Overview: XRTX.V
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX.V
View MoreValuation Measures
Market Cap
5.45M
Enterprise Value
2.23M
Trailing P/E
9.81
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.14%
Return on Equity (ttm)
-29.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.48M
Diluted EPS (ttm)
0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
3.08M
Total Debt/Equity (mrq)
3.10%
Levered Free Cash Flow (ttm)
-1.85M